An ex vivo investigation into the transurothelial permeability and bladder wall distribution of the non-steroidal anti-inflammatory ketorolac 
Introduction
Intravesical drug delivery (IDD), the most common form of transurothelial drug delivery, takes advantage of the bladder's unique anatomy to allow the prolonged exposure of high concentrations of drug to the bladder's luminal surface, whilst minimising systemic absorption.
IDD therefore overcomes the shortcomings of systemic therapy, which is often ineffective due to poor bladder bioavailability and unwanted adverse effects 1,2 .
However, the effectiveness of IDD is limited by several intrinsic properties of the bladder. A specialised, highly impermeable epithelial layer, known as the urothelium, lines the luminal surface. The urothelium is an exceptional barrier with reported transepithelial resistances ranging from 10,000 to 75,000 Ω cm 2 3 ; these represent some of the highest values of all epithelia measured to date 4 . The urothelium is the primary barrier to the movement of molecules from the urine into the blood and will limit the extent to which drugs can permeate into the bladder wall 1 .
Additionally urine flows into the bladder at a constant rate (1 ml min -1 ) 5 diluting the concentration of instilled drug and the need to regularly void the bladder means any drug load will subsequently be lost, reducing exposure time to the bladder wall. Whilst IDD has historically been used as a method for delivering drugs locally to the lower urinary tract, it is inevitable that future developments will seek to improve both controllability and sustainability of therapeutic strategies by incorporating drugs into devices such as ureteral stents 6, 7 .
Despite having been used for a number of decades, intravesical dosing regimens remain largely empirical. This subject has received some attention with investigations into the bladder wall permeation of common intravesical solutions [8] [9] [10] , as well as the effect of permeation enhancers such as chitosan and dimethyl sulfoxide [11] [12] [13] . Recently it has been shown that enhanced bladder wall uptake can be achieved using nanoparticle delivery systems for superficial bladder cancer [14] [15] [16] [17] [18] .
Despite this, many questions remain unanswered about the ability of different drugs to permeate across the urothelium and ultimately the viability of delivering drugs in this manner. In vivo data from IDD studies is limited, due to the difficulty in obtaining bladder tissue concentrations in human and animal subjects, and therefore dosing regimens are typically based on perceived clinical benefits. Although qualitative end points are clinically useful, quantitative data on urothelial permeability and bladder tissue distribution is far more important when predicting the usefulness of new local drug delivery approaches. Research of this kind has clear clinical translation and is key if we are to maximise the potential of delivering drugs locally to the urinary tract.
The primary aim of the current study was to improve our knowledge of IDD by probing the permeability of the bladder wall in an ex vivo setting. To this end we have investigated ketorolac, a non-steroidal anti-inflammatory drug (NSAID) commonly used in urological practice in the US, as an exemplar. We describe an ex vivo approach for estimating local tissue drug concentrations achievable after IDD, which can be used not only to predict the usefulness of prospective therapies but also to optimise existing dosing regimens.
Experimental section

Bladder preparation
Porcine bladders, from pigs weighing 70-90 kg, were obtained fresh from a local abattoir within five minutes of excision and transported in ice-cold oxygenated Krebs buffer back to the laboratory. Bladders were filled and drained with 37 °C saline to remove any residual urine.
Using a scalpel, excess perivesical fat was trimmed away and a single straight-line incision made along the length of the bladder exposing the right and left lateral sides. The bladder was cut into 2 cm 2 sections from the lateral sides and dome area and loaded into glass Franz-type diffusion cells ( Figure 1 ) (Permegear Inc, Hellertown, PA, USA) with the urothelium facing upwards.
Care was taken to avoid contact with the urothelial surface and a metal clamp was used to secure the tissue between the donor and receiver chambers of the in the Franz-type cells. The receptor compartment was filled with oxygenated Krebs buffer and equilibrated at 37 °C for 30 min with a micro stirrer bar providing continuous stirring. A solution of the drug was pipetted into the donor chamber which was covered with a glass disc to prevent evaporative loss. The sampling arm was capped and the Franz-type cells placed in to a thermostatically controlled water bath, maintained at 37 °C, on top of a submersible magnetic stirrer plate. The viability of the bladder tissue over 5 h was evaluated in an assay investigating the copermeation of propranolol hydrochloride (≥ 99%, Acros Organics, Geel, Belgium) and sodium fluorescein (≥ 95%, Sigma-Aldrich Ltd, Dorset, England) across the urothelium and lamina propria. A 500 l aliquot of a saline solution of 1 mM propranolol hydrochloride and 0.1 mM sodium fluorescein was added to the donor chamber of the Franz-type cell. At fixed time points (0.5, 1.5, 3.5 and 5 h), the contents of the receptor and donor chambers were collected and the tissue sample removed.
Prior to removal with a cork borer, the area of tissue in contact with the drug was subjected to three saline rinses (1 ml each rinse) to remove any adsorbed drug and the urothelium and lamina propria carefully separated from the underlying detrusor muscle by cutting along the natural 
Scanning electron microscopy
To investigate the possibility of urothelial cell desquamation or morphological changes to urothelial surface, bladder tissue was examined by scanning electron microscopy (SEM).
Bladder sections were loaded into Franz-type diffusion cells and 500l of normal saline, ketorolac 1.1 mg ml -1 in saline or protamine sulfate 10 mg ml -1 in saline added to the donor chamber. After 90 minutes the contents of the donor chambers were removed, the urothelial surface subjected to three saline rinses (1 ml each rinse) and the tissue sample removed. An additional sample, which was fixed at the abattoir approximately 10 minutes after slaughter, was examined as a control. Sections of tissue (2 x 
Distribution of ketorolac into the bladder wall
Franz-type cells were assembled as described (2.1) and a 500 l aliquot of a 1.1 mg ml -1 ketorolac solution (normal saline) was applied to the donor chamber. After 90 min the Franztype cells were dismantled and the urothelial surface rinsed with saline following collection of the donor and receiver compartments. The area of drug contact was isolated, fixed in OCT and tissue samples sectioned using a cryostat as described (2.2.1). Care was taken to ensure OCT was only present on the serosal side of the tissue. Samples were serially sectioned parallel to the urothelial surface at 50 μm thickness and sections collected in pre-weighed 1.5 ml eppendorf tubes. Tissue sections between 0 and 200 μm (urothelium) were collected individually for analysis, whilst five tissue sections between 200 and 1200 μm (lamina propria) and ten tissue sections between 1200 and 3200 (detrusor muscle) were collected and pooled for analysis. For pooled samples, tissue depths were expressed as the midpoint depth of the sections. Tissue sections were then weighed, extracted in 500 l methanol for 24 hours and drug quantified using HPLC as described (2.3.1). Average tissue concentrations achieved in the urothelium, lamina propria, detrusor muscle and whole bladder wall were calculated by dividing the total amount of drug recovered by the total weight of tissue in that layer.
Determination of the muscle to saline partition coefficient for ketorolac
Detrusor muscle was isolated by removing the urothelium and lamina propria as described (2.2.1) and then turning the tissue over to excise the adventitia and serosa in the same manner.
Muscle sections were then weighed, placed in a capped 10 ml glass collecting vial and submerged in 3 ml of 11 μg ml -1 ketorolac solution (normal saline). The drug solution was sampled at pre-defined time points (1, 1.5, 2, 4 and 6 h) and at 6 h the muscle section was removed and ketorolac extracted to allow the muscle/saline partition coefficient to be calculated. 
Confirmation of tissue viability
Sodium fluorescein and propranolol hydrochloride are recognised paracellular and transcellular markers respectively 23, 24 . In this study the two compounds have been used to evaluate the integrity of the urothelial barrier over 5 h. The results presented in Figure 2A show the amount permeated through the urothelium and lamina propria for each marker over time calculated by summing the amount of drug extracted from the detrusor muscle and any drug recovered from the receptor compartment. Permeability coefficients (K p ) were calculated to be 5.1 x 10 -6 cm s -1 and 1.3 x 10 -6 cm s -1 for propranolol hydrochloride and sodium fluorescein respectively. Figure 2B shows the successful removal of the urothelium and lamina propria (U/LP) leaving the underlying detrusor muscle (M).
Deviation from baseline TEER across the bladder mucosa was investigated after the application of saline and ketorolac to the urothelium (Supplementary data S.1). All mucosa samples used had baseline TEER values greater than 500 .cm 2 , indicative of tight epithelia 25 .
TEER values decreased marginally with time and after 90 min mucosa exposed to saline and ketorolac exhibited 82 and 85 % of baseline TEER respectively. At the end of the experiment (2.5 h) values were 77 and 78 % of baseline TEER for saline and ketorolac respectively. There was no significant difference in TEER reduction between samples exposed to saline or ketorolac at any timepoint (p = 0.511 for 1.5 h timepoint. Significance calculated using two-tailed, unpaired, student's t-test).
The integrity of the ex vivo bladder urothelium was analysed by SEM ( Figure 3 ). Tissue In this experiment, unlike in 3.1, there was no separation of the urothelium and lamina propria from the detrusor muscle. This was a case of experimental improvement; studies in our lab showed that after multiple saline washes of the urothelial surface any remaining adsorbed drug was within error of the amounts calculated from tissue extraction. Therefore any drug extracted after the saline rinse is considered to have permeated the urothelium making the separation step unnecessary. Drug that had permeated the urothelium was calculated by summing drug extracted from the tissue and any drug recovered from the receptor compartment. Drug was only present in receiver samples for the 5 hr time point, constituting 0.2% of the applied dose. The profile in Figure 4A shows that after 5 h approximately 60 g cm -2 of ketorolac had permeated into the bladder wall. A K p value of 2.63 x 10 -6 cm s -1 was calculated for ketorolac across the urothelium.
Mass balance studies showed that on average 93% of the applied dose was recovered per sample ( Figure 4B ).
The distribution of ketorolac into the bladder wall after 90 min is shown in Figure 5 . As expected drug concentrations declined with tissue depth with average concentrations of 400, 141
and 21 µg g -1 achieved in the urothelium, lamina propria and detrusor muscle respectively. After 90 min the average concentration in the whole bladder wall was calculated to be 87 µg g -1 . (n = 5 bladders ± SD).
Determination of the muscle/saline partition coefficient for ketorolac
The concentration of ketorolac solution decreased until equilibrium is established at approximately 2 h ( Figure 6A ). At equilibrium (2-6 h) the ketorolac concentration was 9.5 µg ml -1 and 6.4 µg ml -1 in the solution and detrusor muscle respectively ( Figure 6B ), thus giving a muscle/saline partition coefficient of 0.67. processes that are otherwise absent in our static ex vivo experiments. Total urine production by the kidneys was assumed to be 1 ml min -1 . Although this rate can vary, 1 ml min -1 is a well accepted value for adults [27] [28] [29] . For full explanations of the equations / constants utilised in the PK model see supplementary data S.3. Figure 8 was generated by the model and shows the effects of clearance and dilution on the intravesical delivery process. The constant production of urine will dilute the concentration of drug in the bladder lumen (Fig 8A and B) , which is the driving force for the passive diffusion of drug into the bladder wall. The model predicts that this gives rise to a 42% decrease in the drug concentration achieved in the bladder wall after 90 minutes (Fig 8C) . Vascular clearance continually carries drug from the bladder tissue into the systemic circulation. The model suggests that this will result in a 24% decrease in bladder wall drug concentration after 90 minutes ( Fig   8D) . The combination of the dilution effect of the urine and the clearance of drug from the bladder wall results in a predicted 58% decrease in the overall drug concentration achieved in the bladder wall at 90 minutes (Fig 8E) .
Systemically++ cleared+drug+
Concentra3on+of+drug++ in+bladder+lumen+
Total+volume+in+ bladder+lumen+ T r a n s u r o t h e li a l+ f l u x + Intermediate++ Permea3on+stock+ (note the luminal drug concentration decreases even in the absence of urine production (1100 to 1069 g ml -1 ) due to transurothelial permeation, which is taking place in both scenarios).
Subsequently, this results in a 42% decrease in the drug concentration achieved in the bladder wall (C). In the absence of urine production, but including an estimate for vascular clearance, a 24% decrease in the drug concentration achieved in the bladder wall is predicted (D). The combination of urine dilution and clearance gives rise to a 58% decrease in the bladder wall drug concentration (E).
Discussion
The aim of this study was to investigate the transurothelial delivery and bladder wall distribution of the NSAID ketorolac using an ex vivo porcine model.
Porcine bladder tissue was a natural choice for our ex vivo experiments owing to the long history of pigs being used as animal models in urology. A number of studies have reported the physiology of the urinary tract of pigs to be similar to that of humans [30] [31] [32] .
It was important to ensure that the urothelium remained viable throughout the course of our experiments. A viable barrier would be expected to not only prevent significant permeation, but also differentiate between the transcellular and paracellular movement of molecules. The integrity of the urothelium was evaluated over 6.5 h using two established markers of TEER is an established method of investigating the paracellular permeability of the urothelium [34] [35] [36] [37] . By assessing the resistance across bladder mucosa we can evaluate the maintenance of the tight junctions between umbrella cells crucial to the barrier function of the urothelium. Porcine bladder mucosa exposed to saline (control) or ketorolac showed no significant difference in TEER reduction at any timepoint (2.1 and supplementary data S.1). In addition to alterations in tight junction permeability, an increase in paracellular permeability may result from epithelial cell loss 34 . Using SEM we microscopically examined the superficial surface of the ex vivo porcine bladder tissue to elucidate urothelial integrity (2.2.3). After 90 minutes the application of saline or ketorolac to bladder tissue loaded in the Franz-cell setup had no significant effect on the morphology of the urothelium (Fig 3 and supplementary data S. 2).
Scallop-shaped, superficial umbrella cells with intact tight junctions were evident and closely resembled that reported by others [38] [39] [40] . Protamine sulfate in a concentration of 10 mg ml -1 has been shown to cause immediate umbrella cell sloughing accompanied by a significant decrease in TEER across the urothelium 38 . For this reason protamine sulfate was used as negative control.
The urothelium of bladder tissue exposed to protamine sulfate showed a significant loss of integrity with widespread umbrella cell lysis and subsequent exposure of the underlying intermediate cells (Fig 3C and supplementary data S. 2).
In combination, the results of investigations into paracellular permeation, TEER and SEM analysis suggest that the ex vivo porcine bladder tissue was appropriate for use in our studies.
Recently, Beiko et al 41 evaluated the safety and effectiveness of localised, intravesical ketorolac (1.1 mg ml -1 ) to reduce ureteral stent-related pain. They found a significant reduction in stent-related pain 1 h after stent placement when compared to the control group. While this latest development provides an opportunity for advancing in the management of stent-related pain, its translation into effective patient management will undoubtedly benefit from an understanding of the rate and extent of delivery of ketorolac into the bladder wall. By gathering information regarding the barrier properties of the urothelium and investigating, in quantitative terms, ketorolac delivery, we can begin to make predictions about the viability of delivering ketorolac intravesically and the bladder tissue concentrations necessary to bring about a therapeutic effect. We chose therefore to use a 1.1 mg ml -1 ketorolac solution in our ex vivo studies. According to the mean urination time reported, ketorolac would have been voided from the bladder after approximately 90 min explaining our use of this endpoint.
Although the exact aetiology of stent-related pain is unclear, a common theory is that the distal curl of the ureteral stent irritates the urothelium resulting in spasm, aperistalsis and pain 42 .
Prostaglandins have been shown to produce contractions of isolated detrusor muscle in vitro 43 and their synthesis can be initiated by detrusor muscle stretch and bladder urothelial damage 44 .
Blocking prostaglandin synthesis with indomethacin, a non-selective cyclooxygenase (COX) inhibitor, has recently been shown to decrease acetylcholine-mediated autonomic contractions in the isolated bladder 45 . In addition, afferent C-fibres terminating in the urothelium and lamina propria are known to respond to prostaglandins released (from cells in the urothelium and lamina propria) in response to injury 46 ; suggesting the possibility that, by inhibiting mediators released from urothelial and lamina propria cells, intravesically delivered NSAIDs (such as ketorolac) may provide pain relief in part via modulation of sensory pathways.
The NSAID ketorolac nonselectively inhibits cyclooxygenase 1 and 2 (COX-1 and COX-2), the enzymes responsible for the production of prostaglandins and has been shown to inhibit ureteral contractility in vitro 47 . It follows that by reducing inflammation and spasm, ketorolac should be beneficial in reducing stent-related pain thus explaining its choice by Beiko et al 41 .
Our permeation study ( Figure 4A ) shows that ketorolac is capable of permeating across the urothelium (K p value = 2.63 x 10 -6 cm s -1 ). The production of prostaglandins within the bladder wall is well established with synthesis occurring not only in the detrusor muscle but also from within the urothelium and lamina propria 43, [48] [49] [50] , both of these regions can therefore be taken to be targets for the IDD of ketorolac. In agreement with others who have performed concentrationdepth studies on ex vivo porcine bladder, our distribution study ( Figure 5 ) shows a linear decrease in drug concentration over the urothelium, followed by an exponential decrease in concentration over the lamina propria and detrusor muscle 12, 14 . After 90 min the total concentration in these target regions was 87 µg g -1 .
To address the absence of dilution by urine and vascular drug clearance from the bladder wall in our experiments, a PK bladder model was built using STELLA ® . By visualising complex differential equations, STELLA ® enables users to build dynamic models of highly complex systems. The models can be used to investigate the contribution of different variables on the system as a whole. STELLA ® is therefore suited to pharmacokinetic (PK) modelling and has been used to develop a range of models including PK profiles for enteric tablets 51 , the enhanced oral bioavailability of lipid formulations 52 and ocular permeation following the topical application of drugs 53, 54 .
Only two intravesical PK models have previously been reported for investigating the effect of physiological and pharmacological parameters upon drug concentrations achieved in the bladder wall 55, 56 . The most well known of these was developed in the early nineties by Wientjes et al who used computer-based PK simulations to suggest the optimum dosing strategy for the intravesical delivery of mitomycin C 55 . In contrast to these previous approaches, the userfriendly model described in this study delivers a high resolution PK prediction based on the simultaneous solution of multiple interconnected differential equations. In addition, the speed and flexibility of STELLA ® allows the user to rapidly generate a range of PK simulations by varying determinants such as the rate of urine production, residual urine volume or transurothelial permeation rate. STELLA's ® graphical capabilities allow simulations be explored in real time allowing a better and faster understanding of the dynamic processes underlying the intravesical drug delivery process. This capability will be valuable clinicians wishing to explore intravesical dosing regimens for different drugs in the future. We are the first group to demonstrate this kind of real-time, intravesical PK simulations. A muscle/saline partition coefficient was determined to provide an estimate for the in vivo muscle/blood partition coefficient for ketorolac. Using this, in conjunction with the calculated K p value, the PK model was designed to incorporate both the predicted effects of drug clearance and dilution by urine into our permeation data. Vascular clearance and dilution by urine have independent effects on the concentrations of drug achieved in the bladder wall (Fig 8) . Importantly the dilution effect was shown to be the more significant of the two, resulting in a predicted 42% decrease in bladder wall drug concentration at 90 minutes (Fig 8C) . Our pharmacokinetic model suggests that, due to dilution and vascular clearance, in vivo drug concentrations may be 58 % lower than the tissue concentrations determined in the ex vivo studies ( Figure 5E ). Applying this correction factor to the results from the ex vivo distribution study ( Figure 5 ) predicts a 90 minute bladder wall drug concentration of 37 µg g -1 .
The reported potency of ketorolac, in terms of IC 50 suggesting that levels of ketorolac in the bladder wall would be pharmacodynamically appropriate to provide an anti-inflammatory effect.
In conclusion, using an ex vivo porcine approach we have studied the transurothelial permeation of ketorolac and quantitatively investigated its delivery into the different layers of the bladder wall. Using ketorolac as an example, we have shown how fundamental studies such as these can be used to predict the viability of delivering drugs intravesically in vivo. It would appear that the levels of ketorolac delivered to the bladder wall following IDD are pharmacodynamically appropriate to provide an anti-inflammatory effect. In practice intravesical dosing is largely guided by clinical outcome, with little information available on target drug
concentrations. Investigations such as those described here yield quantitative ex vivo data and predictive in vivo information that can be used to rationally design new transurothelial drug delivery strategies and optimise existing intravesical drug regimens.
